Go Deep
Venus Remedies Limited
Venus Remedies Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,375 | 18.2 | 3.20 | 0.02 | 1,585.50 |
Venus Remedies Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,788,600,000.0 | 2,594,000,000.0 | 1,802,600,000.0 | 1,927,500,000.0 |
| Net Profit | 229,700,000.0 | 474,900,000.0 | 255,800,000.0 | 201,300,000.0 |
| EPS | 17.2 | 35.5 | 19.1 | 15.1 |
Venus Remedies Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 7,345,425,000.0 | 6,472,892,000.0 | 5,914,496,000.0 | 5,533,797,000.0 | — |
| Net Profit | 1,027,890,000.0 | 453,147,000.0 | 284,908,000.0 | 265,658,000.0 | — |
| EPS | 76.9 | 33.9 | 21.3 | 19.9 | — |
Venus Remedies Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 8,537,047,000.0 | 7,157,215,000.0 | 6,268,218,000.0 | 6,010,800,000.0 | — |
| Total Liabilities | 1,899,566,000.0 | 1,547,719,000.0 | 1,392,718,000.0 | 1,407,439,000.0 | — |
| Total Equity | 6,637,481,000.0 | 5,609,496,000.0 | 4,875,500,000.0 | 4,603,361,000.0 | — |
Owes vs Owns
Venus Remedies Limited owed ₹0.22 for every ₹1 it owned in Mar 2026, down from ₹0.23 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.22× | 0.22× | 0.22× | 0.23× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Venus Remedies Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 11.6%Receivables 12.1%Inventory 15.2%Fixed assets (tangible) 22.6%Intangible assets 11.0%Long-term investments 19.2%Other assets 8.4%
How it's funded — Mar 2026
Long-term debt 1.3%Payables 13.3%Other liabilities 7.7%Shareholders' equity 77.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 98.9 | 101.5 | 83.8 | 72.1 |
| Receivables | 103.3 | 112.2 | 80.5 | 76.7 |
| Inventory | 129.4 | 100.5 | 121.7 | 119.9 |
| Fixed assets (tangible) | 193.0 | 153.6 | 155.3 | 163.7 |
| Intangible assets | 94.0 | 104.7 | 85.2 | 79.2 |
| Long-term investments | 163.8 | 54.8 | 0.0 | 0.0 |
| Other assets | 71.4 | 88.4 | 100.3 | 89.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 1.7 | 2.6 | 3.6 |
| Long-term debt | 11.0 | 0.0 | 38.7 | 38.7 |
| Payables | 113.5 | 91.9 | 53.2 | 50.8 |
| Other liabilities | 65.4 | 61.2 | 44.8 | 47.6 |
| Shareholders' equity | 663.7 | 560.9 | 487.6 | 460.3 |
| Net tangible assets | 569.8 | 456.2 | 402.3 | 381.1 |
Venus Remedies Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 1,557,719,000.0 | 864,421,000.0 | 372,854,000.0 | 366,274,000.0 | — |
| Investing Activities | -1,815,689,000.0 | -762,477,000.0 | -72,093,000.0 | -508,296,000.0 | — |
| Financing Activities | -31,153,000.0 | -10,192,000.0 | -10,827,000.0 | -5,675,000.0 | — |